Watanabe Marika, Yakushijin Kimikazu, Funakoshi Yohei, Ohji Goh, Ichikawa Hiroya, Sakai Hironori, Hojo Wataru, Saeki Miki, Hirakawa Yuri, Matsumoto Sakuya, Sakai Rina, Nagao Shigeki, Kitao Akihito, Miyata Yoshiharu, Koyama Taiji, Saito Yasuyuki, Kawamoto Shinichiro, Yamamoto Katsuya, Ito Mitsuhiro, Murayama Tohru, Matsuoka Hiroshi, Minami Hironobu
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, Japan.
Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Vaccines (Basel). 2022 Oct 29;10(11):1830. doi: 10.3390/vaccines10111830.
We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 ( = 2) and loss to follow-up ( = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [ = 15] and mRNA-1273 [ = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone ( = 1), steroids alone ( = 2), or CI combined with steroids ( = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.
我们之前报道过，第二剂BNT162b2对异基因造血干细胞移植（HSCT）患者是安全有效的。在此，我们研究了第三剂新冠病毒mRNA疫苗在异基因HSCT患者中的安全性和有效性。使用QuaResearch新冠病毒人IgM IgG ELISA试剂盒检测针对S1刺突蛋白的抗体滴度。之前的研究纳入了25例接受两剂BNT162b2的异基因HSCT患者。在排除3例因发生新冠病毒感染（n = 2）和失访（n = 1）的患者后，本研究评估了22例接受第三剂新冠病毒mRNA疫苗的异基因HSCT患者（BNT162b2 [n = 15]和mRNA-1273 [n = 7]）。首次接种疫苗时的中位年龄为56岁（范围23 - 71岁）。5例患者在第三次接种时正在接受免疫抑制剂治疗，即单独使用钙调神经磷酸酶抑制剂（CI）（n = 1）、单独使用类固醇（n = 2）或CI联合类固醇（n = 2）。21例患者（95%）在第三剂接种后血清转化。我们的患者在接种疫苗后均未出现严重不良事件、新发移植物抗宿主病（GVHD）或GVHD加重。第三剂BNT162b2和mRNA-1273新冠病毒疫苗对异基因HSCT患者是安全有效的。
